Nordic Nanovector

Nordic Nanovector is a leader in the development of CD37-targeted radionuclide therapies for haematological cancers.

Nordic Nanovector’s pipeline includes:
- Betalutin®, clinically safe and effective CD37-targeting radioimmunotherapy incorporating the beta emitter lutetium-177 and the murine antibody lilotomab for treatment of non-Hodgkin's lymphoma (NHL)
- Humalutin®, IND ready CD37-targeting radioimmunotherapy incorporating the beta emitter lutetium-177 and the chimeric antibody NNV003 for treatment of non-Hodgkin's lymphoma (NHL)
- 89Zr-NNV003, CD37-targeting companion PET diagnostic for detection and dosimetry of CD37 expressing tumors
- Alpha37, a CD37-targeting radioimmunotherapy candidate incorporating the alpha-particle generating radionuclide lead-212,

- Multiple fully humanized anti-CD37 antibodies with different effector mechanisms for treatment of haematological cancers and autoimmune diseases

- Undisclosed discovery projects in solid tumor indications

2009

Worldwide